Adult participants with locally advanced or metastatic EGFR mutation-positive NSCLC participated in an open-label, phase 1b/2 study to determine the safety, maximum tolerated dose (MTD) of RMC-4630 in combination with Osimertinib (a tyrosine kinase inhibitor). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.